Background: There is little information on the possible impact of drugs used in the treatment of multi-drug resistant tuberculosis (MDR-TB) on glycaemic levels. This study therefore assessed changes in glycated haemoglobin levels in patients with MDR-TB.
INTRODUCTION
The increasing incidences of type 2 diabetes mellitus (T2DM) and tuberculosis (TB) worldwide are serious health problems requiring urgent attention. The two disease conditions remain significant causes of morbidity and mortality especially, in the developing countries [1 -3] .
The relationship between DM and TB has been explored by several studies which showed that the risk of TB among diabetics is about 3 times higher than those without diabetes mellitus (DM) (4) even among individuals younger than 40 years of age. Jeon and Murray [4] reported that the diabetes rates among TB patients range from 13% to 50% or even, higher. This is because many TB patients do not know their DM status and therefore, cannot self-report [5] . Also, some TB patients probably died before the manifestation of the classical symptoms of DM, which will warrant DM diagnosis.
The pathophysiology of TB susceptibility in diabetics is not well understood. However, changes in the immune system have been identified to play a prominent role in the pathophysiology [6] . Diabetics have been shown to have impaired innate immune responses to TBwhich worsen the clinical outcomes of TB [3, [7] [8] [9] . This is further compounded with the emergence of multidrug resistance tuberculosis (MDRTB).
MDR-TB is a public health problem due to its increasing trend [10, 11] . Its treatment is challenging as it involves combination of a minimum of 5 drugs for at least 20 months [12] . This challenge becomes daunting when MDR-TB coexists withT2DM as it could cause some adverse events such as delayed sputum culture conversion, treatment failure, increased risk of TB recurrence, deaths, and development of secondary drug resistance [5, 13] .
Although screening for diabetes mellitus is recommended as at the time of diagnosing TB [14] , the use of simple methods such as estimating fasting or random plasma glucose levels as well as oral glucose tolerance test (OGTT) administration have been reported to be problematic and do not correlate perfectly. This has been attributed to the possible interference of TB infection with glycaemic control [5, 15] . This made the estimation of glycatedhaemoglobin (HbA1c) a very useful tool in the determination of glycaemic control in TB patients. HbA1c reflects average blood glucose level over the previous eight to 12 weeks [16] but approximately, 50% of the HbA1c is determined by the blood glucose levels in the preceding 4 weeks.
Due to sole focus on curing MDR-TB, the possible impact of drugs used in the treatment of MDR-TB on glycaemic changes is not usually given appropriate attention. Ethionamide and pyrazinamide have been reported to be rare cause of hypoglycaemia [17, 18] .In diabetics, ethionamide tends to make insulin regimen more difficult, and can result in hypoglycemia and poor glucose regulation [19] .Therefore, it is important to understand the interplay between MDR-TB treatment course and glycaemic changes with a view to helping clinicians make informed decision in the management of MDR-TB patients with diabetes mellitus. Thus, this serves as the basis for this study.
MATERIALS AND METHODS Subjects
This longitudinal study involved a batch of 21 MDR-TB patients at the MDR-TB Referral Centre, University College Hospital (UCH), Ibadan, Nigeria.Usually, the UCH MDR-TB Referral Centre enrolls 2 batches of MDR-TB patients per year. Each batch usually consists of a maximum of 25 patients which are treated over a course of 6 to 8 months. After each batch is discharged, the center is fumigated and kept closed for a month before another batch is admitted. The patients in this study were part of a study which investigated them every 2 months.
Ethical consideration
The study participants were recruited after obtaining an approval from the University of Ibadan/University College Hospital Joint Ethics Review Committee. Also, informed consent was obtained from each participant before enrolment.
Data collection
A short-structured questionnaire was used to obtain information on demographic characteristics, social and medical history. Height (m), body weight (kg) and body mass index (kg/m 2 ) were taken using standard methods.
Sample collection and laboratory analysis About 2 ml of venous blood was collected from each participant into lithium heparin containing sample bottles. Thereafter, glycatedhaemoglobin (HbA1c) level of each sample was determined using an automated boronate affinity assay (Clover A1c ® Self, Infopia Co., Ltd, Korea).
Statistical analysis
Differences in means were assessed using the paired and unpairedStudent's t-test. Results are presented as mean ± standard deviation or frequency (percentage). P-values less than 0.05 were considered as statistically significant.
RESULTS
A total number of 21 MDR-TB patients formed a batch that was admitted into the Referral Centre and they were all enrolled into this study. However, a patient died before the second month sample collection while another was critically ill, therefore, 19 patients completed the study. The patient that died had undiagnosed DM with an HbA1c value of 6.5%.In addition, the patient had HIV infection. The other patient that was critically ill had an HbA1c value of 4.9%.
As shown in Table 1 , 18 patients were underweight while just only one had normal weight (19.27 kg/m 2 ). Also, only one patient has a family history of diabetes.
Comparing the MDR-TB patients without HIV with MDR-TB patients with HIV before the commencement of MDR-TB therapy, the mean body weight, BMI and HbA1c level between the two groups were not significantly different (Table 2) .
Before the commencement of MDR-TB therapy, two patients had pre-diabetes with HbA1c values of 6.0% and 5.8% while the HbA1c values of the remaining patients were less than 5.7%.One of the patients with pre-diabetes had irregular pattern of changes over the course of treatment (6.0%, 4.8%, 5.3% and 6.1% at baseline, 2, 4 and 6 months post-therapy respectively). However, the other patient with pre-diabetes had progressive decline in HbA1c level over the course of treatment (5.8%, 4.9%, 4.6% and 4.5% at baseline, 2, 4 and 6 months post-therapy respectively). There was a significant reduction in the mean HbA1c level at 2 months posttherapy compared with the baseline. H3owever, the HbA1c levels increased slightly after the 2 nd month of therapy but no significant change was observed in the HbA1c levels at 4 and 6 months of MDR-TB therapy compared with baseline (Table 3) .
TABLE 2: GLYACTEDHAEMOGLOBIN LEVELS AND BODY MASS INDEX IN MDR-TB PATIENTS WITHOUT HIV AND MDR-TB PATIENTS WITH HIV BEFORE COMMENCEMENT OF MDR-TB THERAPY MDR-TB-HIV (n = 14)
MDR-TB+HIV (n = 5) 
P-values

DISCUSSION
The interaction between tuberculosis and diabetes mellitus is well established. However, routine screening for diabetes is not routinely carried out on TB patients as many clinicians are not aware of this important link [20 -22] . Also, there is the dearth of information on possible impact of drugs used in the treatment of MDR-TB on glycaemic homeostasis.
Reports have shown that the prevalence of DM among TB patients appears to be high [23, 24] .In this study, majority of the patients had normal HbA1c level while only one patient had pre-diabetes. This observation probably indicates that DM might not be too common among Nigerians with MDR-TB. It is also possible that most TB patients die before DM diagnosis.
Good clinical outcomes have been achieved during a six-month course of tuberculosis treatment using the right combination of drugs to which the infecting M. tuberculosis complex bacilli are susceptible [25] . Based on this, we only monitored the glycaemic changes in the patients in the first 6 months of the MDR-TB treatment. Our observed significant reduction in HbA1c level at 2 months post therapy compared with baseline could indicate that MDR-TB drug regimen may have an acute effect on glycaemic homeostasis. Tabarsi et al. [13] reported that there were changes in HbA1c during the first three-months of anti-TB treatment. Also, Tag El Din et al. [26] reported that most of the side effects of MDR-TB drugs usually appear within the first 3 months.In addition, our observation could be due to the glucose lowering effects of some of the MDR-TB drug regimen [27] . Holden and Hiltz [17] reported that ethionamide could be a rare cause of hyperglycaemia. Also, Pestana [18] reported that pyrazinamide may cause hypoglycemia. Although HbA1cis not a good measure of hypoglycaemia, Lipska et al. [28] reported that severe hypoglycemia was common among patients with type 2 diabetes across all levels of glycemic control and that the risk tended to be higher in patients with either near-normal glycaemia or very poor glycemic control.
Although the aim of this study was not to assess BMI, the observed low BMI in MDR-TB patients before commencement of therapy further supports the widely reported malnutrition in TB patients. Tang et al. [29] showed that low BMI is an independent risk factor for poor outcome in patients with MDR-TB.
Therefore, improvement on nutritional status of MDR-TB patients may facilitate favourable treatment outcome.
Inability to determine fasting plasma glucose (as fasting samples could not be ensured in the patients), glycated albumin or fructosamine are some of the limitations in this study.
It could be concluded from this study that diabetes mellitus is not common among Nigerians with MDR-TB and that MDR-TB drug regimen might have an acute, but not a prolonged, effect on glycaemic changes in MDR-TB patients. Therefore, there is need for tight glycaemic monitoring in MDR-TB patients with diabetes mellitus at the early months of commencement of MDR-TB treatment with a view to achieving optimal glycaemic control.
